You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

KERYDIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Kerydin patents expire, and when can generic versions of Kerydin launch?

Kerydin is a drug marketed by Anacor Pharms Inc and is included in one NDA.

The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the tavaborole profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Kerydin

A generic version of KERYDIN was approved as tavaborole by ENCUBE on October 13th, 2020.

  Try a Trial

Drug patent expirations by year for KERYDIN
Drug Prices for KERYDIN

See drug prices for KERYDIN

Recent Clinical Trials for KERYDIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
PfizerPhase 4

See all KERYDIN clinical trials

Paragraph IV (Patent) Challenges for KERYDIN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
KERYDIN Topical Solution tavaborole 5% 204427 13 2018-07-09

US Patents and Regulatory Information for KERYDIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Anacor Pharms Inc KERYDIN tavaborole SOLUTION;TOPICAL 204427-001 Jul 7, 2014 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for KERYDIN

When does loss-of-exclusivity occur for KERYDIN?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 06214247
Estimated Expiration: ⤷  Try a Trial

Patent: 06333527
Estimated Expiration: ⤷  Try a Trial

Patent: 10203096
Estimated Expiration: ⤷  Try a Trial

Patent: 11200994
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 0608431
Estimated Expiration: ⤷  Try a Trial

Patent: 0621279
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 97982
Estimated Expiration: ⤷  Try a Trial

Patent: 35680
Estimated Expiration: ⤷  Try a Trial

China

Patent: 1160124
Estimated Expiration: ⤷  Try a Trial

Patent: 1505603
Estimated Expiration: ⤷  Try a Trial

Patent: 1914109
Estimated Expiration: ⤷  Try a Trial

Patent: 2532180
Estimated Expiration: ⤷  Try a Trial

Patent: 5949230
Estimated Expiration: ⤷  Try a Trial

Patent: 6008571
Estimated Expiration: ⤷  Try a Trial

Patent: 6008583
Estimated Expiration: ⤷  Try a Trial

Cyprus

Patent: 16454
Estimated Expiration: ⤷  Try a Trial

Patent: 20695
Estimated Expiration: ⤷  Try a Trial

Patent: 24503
Estimated Expiration: ⤷  Try a Trial

Patent: 20027
Estimated Expiration: ⤷  Try a Trial

Denmark

Patent: 43304
Estimated Expiration: ⤷  Try a Trial

Patent: 87796
Estimated Expiration: ⤷  Try a Trial

Patent: 24932
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 53251
Estimated Expiration: ⤷  Try a Trial

Patent: 76536
Estimated Expiration: ⤷  Try a Trial

Patent: 43304
Estimated Expiration: ⤷  Try a Trial

Patent: 87796
Estimated Expiration: ⤷  Try a Trial

Patent: 24932
Estimated Expiration: ⤷  Try a Trial

France

Patent: C1024
Estimated Expiration: ⤷  Try a Trial

Hong Kong

Patent: 09735
Estimated Expiration: ⤷  Try a Trial

Patent: 60139
Estimated Expiration: ⤷  Try a Trial

Patent: 21956
Estimated Expiration: ⤷  Try a Trial

Patent: 28917
Estimated Expiration: ⤷  Try a Trial

Hungary

Patent: 26021
Estimated Expiration: ⤷  Try a Trial

Patent: 40060
Estimated Expiration: ⤷  Try a Trial

Patent: 54365
Estimated Expiration: ⤷  Try a Trial

Patent: 000019
Estimated Expiration: ⤷  Try a Trial

Israel

Patent: 5080
Estimated Expiration: ⤷  Try a Trial

Patent: 2402
Estimated Expiration: ⤷  Try a Trial

Patent: 7156
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 38912
Estimated Expiration: ⤷  Try a Trial

Patent: 46876
Estimated Expiration: ⤷  Try a Trial

Patent: 09140
Estimated Expiration: ⤷  Try a Trial

Patent: 08535781
Estimated Expiration: ⤷  Try a Trial

Patent: 09526751
Estimated Expiration: ⤷  Try a Trial

Patent: 10248265
Estimated Expiration: ⤷  Try a Trial

Patent: 13018778
Estimated Expiration: ⤷  Try a Trial

Patent: 14132031
Estimated Expiration: ⤷  Try a Trial

Patent: 15117243
Estimated Expiration: ⤷  Try a Trial

Patent: 16020374
Estimated Expiration: ⤷  Try a Trial

Patent: 16199561
Estimated Expiration: ⤷  Try a Trial

Patent: 17105826
Estimated Expiration: ⤷  Try a Trial

Lithuania

Patent: 343304
Estimated Expiration: ⤷  Try a Trial

Patent: 2020524
Estimated Expiration: ⤷  Try a Trial

Luxembourg

Patent: 0157
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 5993
Estimated Expiration: ⤷  Try a Trial

Patent: 9262
Estimated Expiration: ⤷  Try a Trial

Netherlands

Patent: 1049
Estimated Expiration: ⤷  Try a Trial

New Zealand

Patent: 0448
Estimated Expiration: ⤷  Try a Trial

Patent: 8297
Estimated Expiration: ⤷  Try a Trial

Patent: 8441
Estimated Expiration: ⤷  Try a Trial

Poland

Patent: 53251
Estimated Expiration: ⤷  Try a Trial

Patent: 43304
Estimated Expiration: ⤷  Try a Trial

Patent: 87796
Estimated Expiration: ⤷  Try a Trial

Patent: 24932
Estimated Expiration: ⤷  Try a Trial

Portugal

Patent: 53251
Estimated Expiration: ⤷  Try a Trial

Patent: 43304
Estimated Expiration: ⤷  Try a Trial

Patent: 87796
Estimated Expiration: ⤷  Try a Trial

Patent: 24932
Estimated Expiration: ⤷  Try a Trial

Russian Federation

Patent: 14906
Estimated Expiration: ⤷  Try a Trial

Patent: 06947
Estimated Expiration: ⤷  Try a Trial

Patent: 07134429
Estimated Expiration: ⤷  Try a Trial

Patent: 08131324
Estimated Expiration: ⤷  Try a Trial

Patent: 10133524
Estimated Expiration: ⤷  Try a Trial

Patent: 16145916
Estimated Expiration: ⤷  Try a Trial

Slovenia

Patent: 43304
Estimated Expiration: ⤷  Try a Trial

Patent: 87796
Estimated Expiration: ⤷  Try a Trial

Patent: 24932
Estimated Expiration: ⤷  Try a Trial

South Africa

Patent: 0707408
Estimated Expiration: ⤷  Try a Trial

Patent: 0905950
Estimated Expiration: ⤷  Try a Trial

Patent: 1005380
Estimated Expiration: ⤷  Try a Trial

Patent: 1506944
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 1337045
Estimated Expiration: ⤷  Try a Trial

Patent: 1337068
Estimated Expiration: ⤷  Try a Trial

Patent: 1426220
Estimated Expiration: ⤷  Try a Trial

Patent: 1456815
Estimated Expiration: ⤷  Try a Trial

Patent: 070112390
Estimated Expiration: ⤷  Try a Trial

Patent: 080110984
Estimated Expiration: ⤷  Try a Trial

Patent: 100105869
Estimated Expiration: ⤷  Try a Trial

Patent: 130095330
Estimated Expiration: ⤷  Try a Trial

Patent: 130100019
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 14095
Estimated Expiration: ⤷  Try a Trial

Patent: 40966
Estimated Expiration: ⤷  Try a Trial

Patent: 86981
Estimated Expiration: ⤷  Try a Trial

Patent: 72962
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering KERYDIN around the world.

Country Patent Number Title Estimated Expiration
Israel 207156 מולקולות קטנות המכילות בור (Boron-containing small molecules) ⤷  Try a Trial
New Zealand 598441 BORON-CONTAINING SMALL MOLECULES ⤷  Try a Trial
Poland 3424932 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for KERYDIN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2343304 2020/024 Ireland ⤷  Try a Trial PRODUCT NAME: CRISABOROLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTRATION NO/DATE: EU/1/19/1421/001 EU/1/19/1421/004 20200327
2343304 CR 2020 00022 Denmark ⤷  Try a Trial PRODUCT NAME: CRISABOROLE, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/19/1421 20200401
2343304 2090017-1 Sweden ⤷  Try a Trial PRODUCT NAME: CRISABOROLE, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT; REG. NO/DATE: EU/1/19/1421 20200401
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.